Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study

JENSEN, Poul Erik Hyldgaard and Warnke, Clemens and Ingenhoven, Kathleen and Piccoli, Luca and Gasis, Marcia and Hermanrud, Christina and Fernandez-Rodriguez, Blanca and Ryner, Malin and Kramer, Daniel and Link, Jenny and Ramanujam, Ryan and Auer, Michael and Buck, Dorothea and Grummel, Verena and Bertotti, Elisa and Fissolo, Nicolas and Oliver-Martos, Begoña and Nytrova, Petra and Khalil, Michael and Guger, Michael and Rathmaier, Sandra and Sievers, Claudia and Lindberg, Raija and Hässler, Signe and Bachelet, Delphine and Aktas, Orhan and Donnellan, Naoimh and Lawton, Andy and Hemmer, Bernhard and Havrdova, Eva Kubala and Kieseier, Bernd and Hartung, Hans-Peter and Comabella, Manuel and Montalban, Xavier and Derfuss, Tobias and Sellebjerg, Finn and Dönnes, Pierre and Pallardy, Marc and Spindeldreher, Sebastian and Broët, Philippe and Deisenhammer, Florian and Fogdell-Hahn, Anna and Sorensen, Per Soelberg (2019) Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of neuroimmunology, 326. pp. 19-27. ISSN 01655728

Abstract

Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.

Item Type: Article
Keywords: multiple sclerosis; interferon-beta; luciferase-based bioassay; bridging ELISA; anti-drug antibodies; neutralizing antibodies
Date Deposited: 29 Nov 2018 00:45
Last Modified: 29 Nov 2018 00:45
URI: https://oak.novartis.com/id/eprint/38284

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.